ABCA1 expression and statins: Inhibitory effect in peripheral blood mononuclear cells

Pharmacogenomics

Volumn 10, Issue 6, 2009, Pages 997-1005

  Genvigir, Fabíana D V ^a   Hirata, Mario H ^a   Hirata, Rosario D C ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ABCA1; Gene expression; HDL; Mononuclear cells; SNP; Statins

Indexed keywords

ABC TRANSPORTER A1; ATORVASTATIN; COMPACTIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; DNA POLYMORPHISM; DRUG EFFICACY; GENE ACTIVATION; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MACROPHAGE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOGENETICS; PHARMACOLOGICAL BLOCKING;

ADULT; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; COHORT STUDIES; FEMALE; GENE EXPRESSION; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEUKOCYTES, MONONUCLEAR; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 69049111160     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.30     Document Type: Article

References (66)

1. Tall AR: Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J. Intern. Med. 263(3), 256-273 (2008).
2. Hersberger M, von Eckardstein A: Low high-density lipoprotein cholesterol: physiological background, clinical importance and drug treatment. Drugs 63(18), 1907-1945 (2003).
3. Krimbou L, Marcil M, Genest J: New insights into the biogenesis of human high-density lipoproteins. Curr. Opin. Lipidol. 17(3), 258-267 (2006).
4. Cavigiolio G, Shao B, Geier EG, Ren G, Heinecke JW, Oda MN: The interplay between size, morphology, stability, and functionality of high-density lipoprotein subclasses. Biochemistry 47(16), 4770-4779 (2008).
5. Timmins JM, Lee JY, Boudyguina E et al.: Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of ApoA-I. J. Clin. Invest. 115(5), 1333-1342 (2005).
6. Francone OL, Subbaiah PV, van Tol A, Royer L, Haghpassand M: Abnormal. phospholipid composition impairs HDL biogenesis and maturation in mice lacking Abca1. Biochemistry 42(28), 8569-8578 (2003).
7. Calpe-Berdiel L, Rotllan N, Palomer X, Ribas V, Blanco-Vaca F, Escolà-Gil JC: Direct evidence in vivo of impaired macrophage-specific reverse cholesterol transport in ATP-binding cassette transporter A1-deficient mice, Biochim. Biophys. Acta 1738(1-3), 6-9 (2005).
8. Oram JF, Heinecke JW: ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol. Rev. 85(4), 1343-1372 (2005).
9. Lee JY, Parks JS: ATP-binding cassette transporter AI and its role in HDL formation. Curr. Opin. Lipidol. 16(1), 19-25 (2005).
10. Brunham LR, Kruit JK, Iqbal J et al.: Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116(4), 1052-1062 (2006).
11. Nofer JR, Remaley AT: Tangier disease: still more questions than answers. Cell. Mol. Life Sci. 62(19-20), 2150-2160 (2005).
12. Bodzioch M, Orsó E, Klucken J et al.: The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22(4), 347-351 (1999).
13. Brooks-Wilson A, Marcil M, Clee SM et al.: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22(4), 336-345 (1999).
14. Marcil M, Brooks-Wilson A, Clee SM et al.: Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 354(9187), 1341-1346 (1999).
15. Rust S, Rosier M, Funke H et al.: Tangier disease is caused by mutations in the gene encoding ATP-biriding cassette transporter 1. Nat. Genet. 22(4), 352-355 (1999).
16. Orsó E, Broccardo C, Kaminski WE et al.: Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and Abc1-deficient mice. Nat. Genet. 24(2), 192-196 (2000).
17. McNeish J, Aiello RJ, Guyot D et al.: High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. USA 97(8), 4245-4230 (2000).
18. Joyce C, Freeman L, Brewer HB Jr, Santamarina-Fojo S: Study of ABCA1 function in transgenic mice. Arterioscler. Thromb. Vasc. Biol. 23(6), 965-971 (2003).
19. Vaisman BL, Lambert G, Amar M et al.: ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J. Clin. Invest. 108(2), 303-309 (2001).
20. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 42(7), 1007-1017 (2001).
21. Santamarina-Fojo S, Peterson K, Knapper C et al.: Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ATP-binding cassette A promoter. Proc. Natl Acad. Sci. USA 97(14), 7987-7992 (2000).
22. Luciani MF, Denizot F, Savary S, Mattei MG, Chimini G: Cloning of two novel ABC transporters mapping on human chromosome 9. Genomics 21(1), 150-159 (1994).
23. Kielar D, Dietmaier W, Langmann T et al.: Rapid quantification of human ABCA1 mRNA in various cell types and tissues by real-time reverse transcription-PCR. Clin. Chem. 47(12), 2089-2097 (2001).
24. Wójcicka G, Jamroz-Wisniewska A, Horoszewicz K, Beltowski J: Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig. Med. Dosw. 61, 736-759 (2007).
25. Schmitz G, Langmann T: Transcriptional regulatory networks in lipid metabolism control ABCA1 expression. Biochim. Biophys. Acta 1735(1), 1-19 (2005).
26. Singaraja RR, Bocher V, James ER et al.: Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing live: X receptor response elements in intron 1. J. Biol. Chem. 276(36), 33969-33979 (2001).
27. Kyriakou T, Hodgkinson C, Pontefract DE et al.: Genotypic effect of the -565C>T polymorphism in the ABCA1 gene promoter on ABCA1 expression and severity of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25(2), 418-423 (2005).
28. Lutucuta S, Ballantyne CM, Elghannam H, Gotto AM Jr, Marian AJ: Novel polymorphisms in promoter region of ATP binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ. Res. 88(9), 969-973 (2001).
29. Hodoglugil U, Williamson DW, Huang Y, Mahley RW: Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. Atherosclerosis 183(2), 199-212 (2005).
30. Zwarts KY, Clee SM, Zwinderman AH et al.: ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clin. Genet. 61(2), 115-125 (2002).
31. Tan JH, Low PS, Tan YS et al.: ABCA1 gene polymorphisms and their associations with coronary artery disease and plasma lipids in males from three ethnic populations in Singapore. Hum. Genet. 113(2), 106-117 (2003).
32. Porchay-Baldérelli I, Péan F, Emery N et al.: Relationships between common polymorphisms of adenosine triphosphate-binding cassette transporter A1 and high-density lipoprotein cholesterol and coronary heart disease in a population with type 2 diabetes mellitus. Metabolism 58(1), 74-79 (2009).
33. Vaughan CJ, Gotto AM Jr: Update on statins: 2003. Circulation 110(7), 886-892 (2004).
34. Gotto AM Jr: Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am. J. Cardiol. 96(54), 34F-38F (2005).
35. Grundy SM, Cleeman JI, Metz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 44(3), 720-732 (2004).
36. Kapur NK, Musunuru K: Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc. Health Risk Manag. 4(2), 341-353 (2008).
37. LaRosa JC, He J, Vupputuri S: Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282(24), 2340-2346 (1999).
38. Wang CY, Liu PY, Liao JK: Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol. Med. 14(1), 37-44 (2008).
39. Basso F, Freeman L, Knapper CL et al.: Role of the hepatic ABCA1 transporter in modulating intrahepatic cholesterol and plasma HDL cholesterol concentrations. J. Lipid Res. 44(2), 296-302 (2003).
40. Haghpassand M, Bourassa PA, Francone OL, Aiello RJ: Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 108(9), 1315-1320 (2001).
41. Aiello RJ, Brees D, Bourassa PA et al.: Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler. Thromb. Vasc. Biol. 22(4), 630-637 (2002).
42. Zanetti I, Favari E, Sposito AC, Rothblat GH, Bernini F: Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem. Biophys. Res. Commun. 321(3), 670-674 (2004).
43. Sone H, Shimano H, Shu M et al.: Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. Biochem. Biophys. Res. Commun. 316(3), 790-794 (2004).
44. Maejima T, Yamazaki H, Aoki T et al.: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun. 324(2), 835-839 (2004).
45. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A: Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J. Pharmacol. Exp. Ther. 311(1), 420-425 (2004).
46. Tamehiro N, Shigemoto-Mogami Y, Kakeya T et al.: Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J. Biol. Chem. 282 (29), 21090-21099 (2007).
47. Wong J, Quinn CM, Brown AJ: Statins inhibit synthesis of an oxysterol ligand for the liver X receptor in human macrophages with consequences fbr cholesterol flux. Arterioscler. Thromb. Vasc. Biol. 24(12), 2365-2371 (2004).
48. Qiu G, Hill JS: Atorvastatin inhibits ABCA1 exprcssion and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J. Cardiovasc. Pharmacol. 51(4), 388-395 (2008).
49. Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ: The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 196(1), 180-189 (2008).
50. Argmann CA, Edwards JY, Sawyez CG et al.: Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA it. ABCA1-mediated cholesterol efflux. J. Biol. Chem. 280(23), 22212-22221 (2005).
51. Wong J, Quinn CM, Gelissen IC, Brown AJ: Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 283(2), 700-707 (2008).
52. Parini P, Gustafsson U, Davis MA et al.: Cholesterol synthesis inhibition elicits an integrated molecular response in human livers including decreased ACAT2. Arterioscler. Thromb. Vasc. Biol. 28(6), 1200-1206 (2008).
53. Guan JZ, Tamasawa N, Murakami H et al.: HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in Type 2 diabetic patients with hyperlipidemia. J. Atheroscler. Thromb. 15(1), 20-25 (2008).
54. Genvigir FD, Soares SA, Hirata MH et al.: Effects of ABCA1 SNPs, including the C-105T novel variant, on serum lipids of Brazilian individuals. Clin. Chim. Acta 389(1-2), 79-86 (2008).
55. Llaverias G, Rebollo, A, Pou J et al.: Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem. Pharmacol. 71(5), 605-614 (2006).
56. Langmann T, Liebisch G, Moehle C et al.: Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim. Biophys. Acta 1740(2), 155-161 (2005).
57. Wellington CL, Walker EK, Suarez A et al.: ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation. Lab. Invest. 82(3), 273-283 (2002).
58. Oram JF, Vaughan AM: ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 99(10), 1031-1043 (2006).
59. Llaverias G, Lacasa D, Viñals M et al.: Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem. Pharmacol. 68(1), 155-163 (2004).
60. Zanotti I, Potì F, Favari E, Steffensen KR, Gustafsson JA, Bernini F: Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP. J. Pharmacol, Exp. Ther. 317(1), 395-401 (206).
61. van Eck M, Bos IS, Kaminski WE et al.: Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc. Natl. Acad. Sci. USA 99(9), 6298-6303 (2002).
62. World Health Organization: Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ. Tech. Rep. Ser. 894(i-xii), 1-253 (2000).
63. Rebecchi IM, Rodrigues AC, Arazi SS et al.: ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem. Pharmacol. 77(1), 66-75 (2009).
64. Arazi SS, Genvigir FD, Willrich MA et al.: Atorvastatin effects on SAEBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response. Clin. Chim. Acta 393(2), 119-124 (2008).
65. Vandesompele J, De Preter K, Pattyn F et al.: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3(7), RESEARCH0034 (2002).
66. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-δ δ C[T]) method. Methods 25(4), 402-408 (2001).